Pliant Therapeutics, Inc. (NASDAQ:PLRX) General Counsel Sells $112,427.70 in Stock

Pliant Therapeutics, Inc. (NASDAQ:PLRX) General Counsel Mike Ouimette sold 10,230 shares of the business’s stock in a transaction that occurred on Wednesday, January 22nd. The shares were sold at an average price of $10.99, for a total value of $112,427.70. Following the completion of the transaction, the general counsel now directly owns 70,544 shares of the company’s stock, valued at $775,278.56. The trade was a 12.66 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.

Mike Ouimette also recently made the following trade(s):

• On Friday, January 17th, Mike Ouimette sold 13,270 shares of Pliant Therapeutics stock. The shares were sold at an average price of $11.20, for a total value of $148,624.00.

Pliant Therapeutics Price Performance

Shares of PLRX stock opened at $10.92 on Friday. The company has a quick ratio of 10.26, a current ratio of 10.26 and a debt-to-equity ratio of 0.09. The stock has a 50 day simple moving average of $13.14 and a 200-day simple moving average of $13.05. Pliant Therapeutics, Inc. has a 1-year low of $10.22 and a 1-year high of $18.92.

Pliant Therapeutics (NASDAQ:PLRX) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($0.95) EPS for the quarter, beating the consensus estimate of ($0.99) by $0.04. As a group, equities research analysts anticipate that Pliant Therapeutics, Inc. will post -3.65 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the company. China Universal Asset Management Co. Ltd. raised its stake in Pliant Therapeutics by 10.3% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 12,903 shares of the company’s stock valued at $170,000 after purchasing an additional 1,209 shares during the last quarter. R Squared Ltd acquired a new position in Pliant Therapeutics in the 4th quarter valued at $33,000. SG Americas Securities LLC raised its stake in Pliant Therapeutics by 27.2% in the 4th quarter. SG Americas Securities LLC now owns 30,729 shares of the company’s stock valued at $405,000 after purchasing an additional 6,579 shares during the last quarter. Hennion & Walsh Asset Management Inc. raised its stake in Pliant Therapeutics by 18.1% in the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 108,608 shares of the company’s stock valued at $1,430,000 after purchasing an additional 16,634 shares during the last quarter. Finally, Harbor Capital Advisors Inc. raised its stake in Pliant Therapeutics by 4.2% in the 4th quarter. Harbor Capital Advisors Inc. now owns 95,801 shares of the company’s stock valued at $1,262,000 after purchasing an additional 3,822 shares during the last quarter. 97.30% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Separately, HC Wainwright reissued a “buy” rating and issued a $38.00 price target on shares of Pliant Therapeutics in a report on Friday, November 8th. Seven investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Pliant Therapeutics has an average rating of “Buy” and an average price target of $40.50.

Pliant Therapeutics Company Profile

Pliant Therapeutics, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis.